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ABSTRACT
CONTEXT AND OBJECTIVES: Package leaflets are necessary for safe use of medicines. The aims of the 
present study were: 1) to assess the compliance between the content of the package leaflets and 
the specifications of the pharmaceutical regulations; and 2) to identify potential safety issues for patients. 
DESIGN AND SETTING: Qualitative descriptive study, involving all the package leaflets of branded medi-
cines from the three most consumed therapeutic groups in Portugal, analyzed in the Department of Phar-
macoepidemiology, School of Pharmacy, University of Lisbon.
METHODS: A checklist validated through an expert consensus process was used to gather the data. The 
content of each package leaflet in the sample was classified as compliant or non-compliant with compul-
sory regulatory issues (i.e. stated dosage and descriptions of adverse reactions) and optional regulatory 
issues (i.e. adverse reaction frequency, symptoms and procedures in cases of overdose).
RESULTS: A total of 651 package leaflets were identified. Overall, the package leaflets were found to be 
compliant with the compulsory regulatory issues. However, the optional regulatory issues were only ad-
dressed in around half of the sample of package leaflets, which made it possible to identify some situations 
of potentially compromised drug safety.
CONCLUSION: Ideally, the methodologies for package leaflet approval should be reviewed and optimized 
as a way of ensuring the inclusion of the minimum essential information for safe use of medicines. 
RESUMO
CONTEXTO E OBJETIVO: As bulas dos medicamentos são necessárias para a sua utilização segura. 
Os objetivos do presente estudo foram: 1) avaliar a adequação entre o conteúdo das bulas e as especifica-
ções da regulação farmacêutica e 2) identificar os aspectos que potencialmente possam comprometer a 
utilização segura dos medicamentos pelos doentes.
TIPO DE ESTUDO E LOCAL: Estudo descritivo qualitativo com a inclusão de todas as bulas dos medica-
mentos de marca dos três grupos terapêuticos mais consumidos em Portugal, analisados no Departamen-
to de Farmacoepidemiologia da Faculdade de Farmácia da Universidade de Lisboa.
MÉTODOS: Utilização de uma checklist para recolher os dados. A checklist foi validada por um processo de 
consenso entre peritos. O conteúdo de cada uma das bulas da amostra foi classificado em relação à ade-
quação aos aspectos regulatórios obrigatórios, como a descrição das reações adversas, dose e frequência 
de administração, e à adequação dos aspectos regulatórios facultativos, como a frequência das reações 
adversas e sintomas e procedimentos em caso de sobredosagem.
RESULTADOS: Foram identificadas 651 bulas. Em termos gerais, todas as bulas foram consideradas con-
formes em relação aos aspectos regulatórios obrigatórios. No entanto, os aspectos regulatórios opcionais 
foram descritos em apenas cerca de metade da amostra de bulas, o que permite a identificação de situa-
ções susceptíveis de comprometer a utilização segura dos medicamentos.
CONCLUSÃO: Idealmente as metodologias de aprovação das bulas devem ser revistas e otimizadas de 
forma a assegurar um mínimo de informação essencial para a utilização segura dos medicamentos.
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INTRODUCTION
Package leaflets are fundamental for the safe and effective use 
of medicines.1,2 Amongst other issues, the European Medicines 
Agency is responsible for the publication of legal requisites 
regarding the content of the package leaflets of medicinal prod-
ucts for human use, such as their template, the Quality Review of 
Documents for Human Product Information.2 
According to the Quality Review of Documents for Human 
Product Information, all package leaflets must include an initial 
content list and be structured in six sections (Table 1).2 All ver-
sions (1 to 9) of the Quality Review of Documents for Human 
Product Information template,2 except the first two, have required 
the presence of the abovementioned content list.3 The first ver-
sion of the Quality Review of Documents for Human Product 
Information was published by the European Medicines Agency in 
1996; however, the United States Food and Drug Administration 
had already been recommending the use of package inserts for 
oral contraceptives, intrauterine contraceptives devices and 
estrogens since 1977.2-4 Package leaflets met resistance and criti-
cism in the past, because at that time their use was associated 
with problems in the physician-patient relationship and in the 
production and distribution of medicinal products.4
Usability testing was pioneered in Australia in the early 1990s, 
with the objective of proving the readability and comprehensibility 
of package leaflets.5 In order to ensure proper and safe use of medi-
cines, the European Medicines Agency also developed specific reg-
ulations on usability testing for package leaflets. The first guide-
line of the European Medicines Agency on the readability of labels 
and package leaflets of medicinal products was approved in 1998 
and reviewed in 2009.6 According to this guideline, “user testing” 
should consist of enrolling a group of patients with the objective 
of identifying comprehension issues in the content of the package 
leaflets; in the event that any readability problem is identified in 
this test, those holding marketing authorization must successively 
act upon the information included in the package leaflets until it is 
completely understood.6-8 Article 59 (3) of Directive 2004/27/EC 
(which amended Directive 2001/83/EC) states that the content of 
the package leaflets shall reflect the results of consultations with 
target patient groups, to ensure their readability.9,10 Infarmed (the 
Portuguese Medicines Agency) issued Law 176/2006,11 which 
takes into account the adoption of both Directives. In accordance 
with this law, the package leaflets should contain the following 
essential elements:
1.  Name of the medicine (including strength and pharmaceuti-
cal form).
2.  Pharmacotherapeutic category.
3.  Therapeutic indications.
4.  Directions or instructions for use (dosage, administration 
route, frequency).
5.  Information on the safety of the medicine (contraindications, 
precautions and interactions).
6.  Adverse reactions.
7.  Expiration date of the medicine.
8.  Qualitative composition (active substances and excipients).
9.  Other relevant information, such as the duration of treat-
ment (or temporal limits) and procedures to be adopted in 
cases of overdose or poisoning (e.g. emergency procedures 
and antidotes).
In accordance with this regulation, “other relevant informa-
tion” (point 9) was classified as optional, so that the description 
in the content of the package leaflets would be dependent on the 
pharmacological characteristics of the medicinal products (e.g. 
package leaflets for medicines with narrow therapeutic margins 
must contain a description of overdose symptoms and specific pro-
cedures in cases of overdose).9-11
A brief bibliographic review, using current databases 
(PubMed, Academic Search Complete and Web of Science) 
regarding the readability of package leaflets, showed that 
there are problems specifically relating to the description of: 
1) duration of treatment,1,12-15 2) adverse reactions12,16-18 and 
3) overdose.19,20 The importance of investigating the readabil-
ity of package leaflets has also been confirmed in other previ-
ous studies.3,8,20 In addition, the use of verbal descriptors (e.g. 
common, rare, not known, etc.) instead of numerical descrip-
tors (e.g. percentages, fractions, etc.) was preferred by patients 
for expressing the frequency of adverse reactions, with results 
that were more favorable than when absolute frequencies were 
used as an alternative to frequency ranges.16-18 Comprehension 
issues regarding dosage and adverse reactions were also previ-
ously identified.12,13 In another study, it was found that less than 
20% of the participants were able to identify the symptoms of 
a rare life-threatening adverse reaction in a package leaflet for 
an antidepressant.1 Other issues, such as the length of the pack-
age leaflet and labeling characteristics (e.g. overdose risk due 
to  inadequate labeling) were also considered relevant to the 
investigation on readability.3,8,19,20 
Table 1. Sections of the package leaflets
Sections*
1 What X is and what it is used for
2 What you need to know before you <take> <use> X
3 How to <take> <use> X
4 Possible side effects
5 How to store X
6 Contents of the pack and other information
*According to the template of the European Medicine Agency Quality Review 
of Documents for Human Product Information version 82; X: name of medicinal 
products.
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Taking into consideration that the readability of package leaf-
lets remains a controversial issue,8,21 that there is a lack of pub-
lished studies about regulatory inconsistencies in Portuguese 
package leaflets and that these issues have only been evaluated 
by marketing authorization holders and the National Medicines 
Agency (i.e. not by other external institutions such as universi-
ties), the relevance of the present study became clear.
OBJECTIVES
The aims of this study were: 1) to assess the compliance between 
the content of the package leaflets and pharmaceutical regulations, 
comprising compulsory issues, such as descriptions of dosages and 
adverse reactions and optional issues, such as duration of the treat-
ment, frequency of administration and overdose symptoms; 2) to 
identify potential safety issues for patients; and 3) to evaluate pos-
sible qualitative inconsistencies within the sample of package leaf-
lets and with package leaflets from other countries.
METHODS
The package leaflets in the sample were from medicines in the 
three most consumed therapeutic groups within the Portuguese 
National Health Service (according to 2009 data),22 i.e. those 
relating to the central nervous system (Group 2 of the Portuguese 
prescribing guide; 33,161,500 units of medicine sold); the cardio-
vascular system (Group 3 of the Portuguese prescribing guide; 
36,337,347 units of medicines sold); and the musculoskeletal sys-
tem (Group 9 of the Portuguese prescribing guide; 14,240,989 
units of medicines sold). The package leaflets of the sample were 
identified online in Infomed (the public database for medicines 
in Portugal), using the Portuguese prescribing guide’s classifica-
tions, between January and March 2012.23,24 
The package leaflets not included were the following:
1.  Package leaflets of medicinal products that are not marketed 
or not authorized, i.e. not available to patients.
2.  Package leaflets of medicinal products used exclusively in 
hospitals.
3.  Package leaflets of generic medicines (i.e. package leaflets very 
similar or equal to the package leaflets of branded products); 
thus, only package leaflets of branded medicines were selected.
4.  Package leaflets without an initial content list (Table 1),2,3 which 
were classified as outliers and excluded from further analysis.
Firstly, each of the package leaflets in the sample was clas-
sified in relation to the type of pharmaceutical strength(s) 
(i.e. dose), pharmaceutical form(s) (e.g. tablets, syrups, etc.), 
prescription status (i.e. prescription only or over-the-counter), 
approval (European Medicines Agency or National Agency) and 
international non-proprietary name(s). Repeated package leaf-
lets (package leaflets including the same text) were also identified 
through application of a manual procedure.
Secondly, the content of each of the package leaflets in the sam-
ple was classified as compliant or non-compliant with the com-
pulsory regulatory issues (i.e. stated dosage and descriptions of all 
adverse reactions), and as compliant or non-compliant with the 
optional regulatory issues (i.e. stated frequency of adverse reactions, 
overdose symptoms and procedures in cases of overdose). To this 
end, the descriptions of these issues in the content of the package 
leaflets were confirmed through application of a verification list or 
checklist (Table 2), thus making it possible to gather data for fur-
ther analysis. The abovementioned compulsory and optional issues 
were specifically selected because, according to the literature, these 
issues are have the most influence on patients’ comprehension.12-18 
Three experts (two regulatory affairs experts and one epidemiolo-
gist) validated the checklist through a consensus technique (indi-
vidual interviews plus mini-Delphi), taking into consideration the 
relevance of each of the variables in the checklist (Table 2). 
Table 2. Checklist used to gather the characteristics of the package leaflets
Checklist
1. Administration
1.1. Quantity to be taken is indicated (e.g. 1 tablet, 1 
teaspoon)
Yes = 1
No = 0
1.2. Frequency of administration (e.g. once a day, every 
6 hours)
Yes = 1
No = 0
1.3. Treatment duration* Yes = 1
No = 0
1.4. Text check: identification of at least one sentence 
in section 3 of the package leaflet (How to 
<take><use> X) that is equal to:†
1.4.1. “Always <take><use> this medicine exactly as 
your <doctor><or><pharmacist> has told you.”
Yes = 1
No = 0
1.4.2. “Check with your <doctor><or><pharmacist> 
if you are not sure.”
Yes = 1
No = 0
1.4.3. “The recommended dose is...” Yes = 1
No = 0
2. Adverse reactions
2.1. Adverse reactions organized according to frequency Yes = 1
No = 0
Not applicable = 3‡
3. Overdose
3.1. Overdose effects described Yes = 1
No = 0
Not applicable = 3
3.2. In cases of an overdose, what to do is indicated§ No action = 0
Action = 1
Other actions = 2
Not applicable = 3
*The duration of the treatment must be indicated for at least one of the medicine 
indications (or alternatively the minimum or maximum recommended duration); 
†Phrases in accordance with the European Medicine Agency Quality Review of 
Documents for Human Product Information version 82; ‡not applicable (package 
leaflets not describing adverse reactions); §actions comprise: consultation with 
doctor or pharmacist or going to a hospital (Action = 1); other actions beyond 
those described in section (1) (e.g. induce vomiting, take activated charcoal, etc.) 
(Other actions = 2); and not applicable for package leaflets of medicines without 
risk of overdose (Not applicable = 3).
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The results from applying the checklist were organized in an 
Excel file. All the data were subjected to a quality control pro-
cedure in accordance with the requisites of the NBR 5425 stan-
dard.25 Subsequently, package leaflets that were non-compliant 
(in relation to the compulsory or optional regulatory issues) 
were ecologically compared with equivalent Portuguese pack-
age leaflets (or package leaflets from medicines with the same 
active substance, pharmaceutical form and dose) and with at 
least one equivalent package leaflet from other countries (pack-
age leaflets selected from public databases of medicines relating 
to the United Kingdom, United States of America and Australia). 
Furthermore, the similarity between the sentences in section 3 
(“How to <take><use> X”) of each package leaflet in the sample 
and the sentences described in section 3 of the Quality Review of 
Documents for Human Product Information version 8 (European 
Medicines Agency template) was also assessed.2 
The Statistical Package for the Social Sciences (SPSS) for Windows 
(version 19.0, IBM-SPSS, Chicago, IL, USA) was used to perform 
the statistical analysis (descriptive statistics and chi-square test). 
The chi-square test was used to identify statistically significant associa-
tions (at a significant level of P < 0.05) between package leaflets from 
the different therapeutic groups and/or countries, taking into consid-
eration their compliance with regulatory issues.
RESULTS
As a consequence of applying the exclusion criteria (Table 3), 
651 package leaflets were selected from the 1,072 package leaflets 
identified in Infomed.23 Thus, 421 package leaflets were excluded 
within the three therapeutic groups: 129 repeated; 181 not avail-
able in the database; 77 classified as outliers or not compli-
ant with the Quality Review of Documents for Human Product 
Information template model;2 and 34 used as hospital medicines. 
With regard to the composition of the medicines, the numbers 
of active substances mentioned in each package leaflet (and quanti-
fied in terms of a number of international non-proprietary names or 
generic names) were, respectively: 189 for Group 2 (or central ner-
vous system); 128 for Group 3 (or cardiovascular system); and 81 for 
Group 9 (or musculoskeletal system). A total of 209 (32.1%) of the 
651 package leaflets were classified as mixed package leaflets, i.e. pack-
age leaflets including descriptions of more than one pharmaceutical 
strength or pharmaceutical form. The medicines in the central ner-
vous system group had the greatest number of different pharmaceu-
tical forms (41), while the package leaflets in the musculoskeletal 
and cardiovascular system groups presented, respectively, 32 and 17. 
Among the 651 package leaflets, 106 (16.3%) were from over-the-
counter drugs (51 in Group 2, 5 in Group 3 and 50 in Group 9).
The results from applying the checklist can be seen in Table 4. 
Only 218 package leaflets (33.5% of 651) described the duration of 
the treatment, of which 123 were in Group 2, 35 in Group 3 and 60 in 
Group 9. Identification of different treatment durations (including 
non-description) was possible within package leaflets of equivalent 
medicines (equal international non-proprietary names, pharma-
ceutical forms and pharmaceutical strength) in at least seven cases. 
On average, from all three therapeutic groups, the following infor-
mation was found: 1) 55.6% of the package leaflets (standard devi-
ation, SD, ± 1.9) provided the frequency of adverse reactions; 
2) 61.9% (SD: ± 17.4) provided the signs and symptoms of an over-
dose situation; and 3) 58.8% (SD: ± 10.1) provided the recommen-
dation that a physician or pharmacist should be consulted in cases 
of overdose. Also on average, only 38.1% of the package leaflets 
(SD: ± 3.9) provided proactive procedures for avoiding intoxica-
tion (107 in Group 2, 67 in Group 3, and 69 in Group 9), such 
as inducing vomiting, taking activated charcoal, lying down, con-
tacting the poison control center and/or other actions. 
In the comparison between the package leaflets of the medi-
cines from the three therapeutic groups, the following was found: 
1) the description of treatment duration (item 1.3 of the check-
list) was positively associated (chi-square = 21.951; P = 0.019) with 
Group 3 (cardiovascular system), in comparison with the other two 
groups (central nervous and musculoskeletal systems); 2) absence of 
a description of overdose symptoms (item 3.1 of the checklist) was 
negatively associated (chi-square = 79.335; P < 0.001) with Group 
2 (central nervous system), in comparison with the cardiovascular 
and musculoskeletal systems groups; and 3) absence of actions to be 
taken in cases of overdose (item 3.2 of the checklist) was also nega-
tively associated (chi-square = 35.982; P < 0.001) with Group 3 (car-
diovascular system), in comparison with Groups 2 and 9.
More importantly, dosage (dose and/or schedule) was omit-
ted from 14 package leaflets (Table 5): 12 (1.8% of 651) did not 
describe the dose and nine (1.4% of 651) did not describe the 
Table 3. Sample of package leaflets: classification and distribution
Therapeutic groups
Central 
nervous
Central 
nervous (%)
Cardiovascular Cardiovascular (%) Musculoskeletal Musculoskeletal (%) Total
1. Package leaflets excluded
1.1. Package leaflets repeated 58 10.7 48 17.0 23 9.3 129
1.2. Package leaflets  not available 114 21.0 43 15.2 24 9.8 181
1.3. Outliers 40 7.4 9 3.2 28 11.4 77
1.4. Package leaflets of hospital medicines 23 4.1 3 1.1 8 3.2 34
2. Sample of package leaflets 309 56.8 179 63.5 163 66.3 651
3. Total number of package leaflets identified 544 100 282 100 246 100 1,072
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Table 4. Results from checklist application
G2  
(n)
G2 (%) 
[309]
G3  
(n)
G3 (%) 
[179]
G9  
(n)
G9 (%) 
[163]
Total
G2+G3+G9
Average (%)
G2+G3+G9
SD
G2+G3+G9
1. Administration
1.1. Dose to be administered NOT described 10 3.2 2 1.1 0 0 12 1.5 1.6
1.2. Frequency of administration NOT described 9 2.9 0 0 0 0 9 1.0 1.7
1.3. Duration of treatment NOT described 186 60.2 144 80.4 103 63.2 433 67.9 10.9
1.4. At least one equal phrase* NOT included 40 12.9 4 2.2 18 11 62 8.7 5.7
2. Adverse reactions
2.1. Adverse reactions NOT described† 3 1.0 0 0 0 0 3 0.3 0.6
2.2. Adverse reaction frequency NOT described 140 45.3 76 42.5 73 44.8 289 44.2 1.5
3. Overdose
3.1. Overdose symptoms NOT described 52 16.8 65 36.3 69 42.3 186 31.8 13.3
3.2. Actions in cases of overdose NOT described 9 2.9 4 2.2 5 3.1 18 2.7 0.4
3.3. Consult a doctor /pharmacist in cases of overdose described 183 59.2 106 59.2 68 41.7 357 53.4 10.1
3.4. Other specific actions in cases of overdose described‡ 107 34.6 67 37.4 69 42.3 243 38.1 3.9
n = number of package leaflets; G = group (taking into consideration the number of package leaflets in each therapeutic group); G2 = Group 2 of the 
Portuguese prescribing guide, relating to the central nervous system; G3 = Group 3, relating to the cardiovascular system; G9 = Group 9, musculoskeletal 
system; SD = standard deviation.
*Package leaflets presenting sentences in accordance with what is described in points 1.4.1; 1.4.2 and 1.4.3 of the checklist (Table 2); †package leaflets of 
medicines free from adverse reactions; ‡for example, induce vomiting or drink water.
Note: the sum of frequencies from points 3.2, 3.3 and 3.4 do not fully correspond to 100%, since for some medicines the occurrence of overdose was not 
considered applicable, such as in the case of some topical forms.
Table 5. Package leaflets presenting dosage omissions 
Dosage omissions†
Generic name* Therapeutic group Dose Frequency of administration Person responsible for administration‡
Botulinum toxin
100 units powder for injectable solution
G2 No Yes Healthcare professional
Haloperidol§
50 mg/1 ml, 100 mg/1 ml injectable solution
G2 No No Healthcare professional
Levodopa + carbidopa
20 mg/ml + 5 mg/ml, intestinal gel
G2 No No Healthcare professional
Levodopa + carbidopa§
25 mg + 100 mg tablets, 25 mg + 250 mg tablets
G2 No No Patient
Levodopa + carbidopa + entacapone
50 mg/12.5 mg/200 mg coated tablets
G2 No No Patient
Mepivacaine
54 mg/1.8 ml injectable solution
G2 No No Healthcare professional
Olanzapine
10 mg powder for injection
G2 Yes No Healthcare professional
Phenobarbital
15 mg tablets
G2 No Yes Patient
Topiramate§
25, 50, 100, 200 coated tablets
G2 No No Patient
Topiramate§
15, 25, 50 capsules
G2 No No Patient
Tramadol§
100, 200, 300 mg extended-release tablets
G2 No Yes Patient
Valproic acid
40 mg/ml syrup
G2 Yes No Patient
Fosinopril
20 mg tablets
G3 Yes No Patient
Ramipril + hydrochlorothiazide§
2.5 mg/12.5 mg, 5 mg/25 mg tablets
G3 Yes No Patient
G2 = Group 2 of the Portuguese prescribing guide, relating to the central nervous system and G3 = Group 3, relating to the cardiovascular system.
*Each generic name corresponds to one package leaflet; †Dose or frequency of administration; ‡Healthcare professional or patient self-administration;  
§Mixed package leaflet.
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frequency of administration. Furthermore, five of the 14 pack-
age leaflets were from medicines that need to be administered by 
healthcare professionals, nine were from medicines that can be 
self-administered by patients. 
These 14 package leaflets comprised 12 international non-
proprietary names, as follows: 1) botulinum toxin; 2) halo-
peridol; 3) levodopa + carbidopa; 4) levodopa + carbidopa; 
5) levodopa + carbidopa + entacapone, 6) mepivacaine; 
7) olanzapine; 8) phenobarbital; 9) topiramate; 10) topiramate; 
11) tramadol; 12) valproic acid; 13) fosinopril; and 14) ramipril 
+ hydrochlorothiazide. Out of the 14 package leaflets, 12 were in 
the central nervous group and two in the cardiovascular group.
Relative to each of the 14 package leaflets without dose 
description (Table 5), it was possible to find at least one pack-
age leaflet of an equivalent medicine (i.e. the same composi-
tion, dosage and pharmaceutical form) available in the United 
Kingdom, United States and Australia. The exceptions were 
fosinopril 20 mg tablets and ramipril + hydrochlorothiazide 
2.5 mg/12.5 mg or 5 mg/25 mg tablets (a mixed package leaflet), 
which apparently were not marketed in these three countries at 
the time of the study. These package leaflets were available for 
public consultation on the websites of the medicines agencies 
and health products authorities, respectively the Medicines and 
Healthcare Products Regulatory Agency (http://www.mhra.gov.
uk/Safetyinformation/Medicinesinformation/SPCandPILs/), 
the Food and Drug Administration (http://www.fda.gov/Drugs/
DrugSafety/ucm085729.htm) and the Therapeutic Goods 
Administration (http://www.tga.gov.au/consumers/informa-
tion-medicines-cmi.htm#.UrMxNPRdV1Y). Similarly to the 
package leaflets for Portuguese medicines, omissions relating to 
dosage (both quantity and frequency of administration) were 
identified in the package leaflets of medicines from these three 
countries (Table 5).
In a subsample of the package leaflets (87 from non-steroi-
dal anti-inflammatory drugs, 33 from angiotensin-converting-
enzyme inhibitors and 27 from anxiolytics/sedatives/hypnotics), 
overdose symptoms were not described in respectively 36.8%, 
24.2% and 11.1%.
DISCUSSION
In the European Union, medicines authorities are responsi-
ble for approving and updating the contents of package leaflets 
(e.g. in the event of urgent safety measures being required).3,26,27 
The scientific committees of the European Medicines Agency 
have developed and implemented diverse regulatory require-
ments in relation to medicinal products, such that manufactur-
ers and marketing authorization holders have to observe these 
laws.2 The lack of scientific publications about package leaflets 
confirms that there is a need for further independent specific 
studies in this area. Moreover, evaluations of package leaflets 
performed outside the legal systems (e.g. in academic centers) 
seem to be scarce, despite the fact that they are clearly advisable 
for safety reasons.
In the present study, the checklist was considered to be a use-
ful and workable screening tool for assessing compliance between 
the content of the package leaflets and some relevant regulatory 
issues. It covered critical issues regarding adequate use of the 
medicines28 and constituted an appropriate method for gather-
ing data, taking into consideration the high number of package 
leaflets and the volume of information available. Although the 
Portuguese medicines were not all approved by a centralized pro-
cedure (under direct coordination from the European Medicines 
Agency), rather through mutual recognition or decentralized or 
national procedures (e.g. under the direct coordination of the 
National Medicines Agencies),29 almost all the package leaflets 
of the sample were developed in accordance with the six sec-
tions of the Quality Review of Documents for Human Product 
Information template,2 which is compulsory for package leaflets 
approved by a centralized procedure, for example.
Mixed package leaflets
Naturally, patients consider that using package leaflets with more 
than one pharmaceutical form and/or strength is more diffi-
cult  than using simple package leaflets (with only one pharma-
ceutical form and/or strength), because simple package leaflets 
present a lower degree of uncertainty regarding instructions on 
how to  use the medicines.30 The possible high complexity asso-
ciated  with interpretation of mixed package leaflets means that 
it is advisable to increase the accuracy of the “end-user testing” 
(e.g. increasing the number of questions about dosage in face-to-
face interviews).30,31 Even though the regulations of the European 
Medicines Agency recommend special care in approving mixed 
package leaflets,30 approximately one third of our sample were clas-
sified as mixed package leaflets. This situation might be explained 
by the fact that the production costs of the mixed package leaflets 
imply lower costs than those associated with the simple package 
leaflets. However, post-commercialization data specifically about 
safe use of mixed package leaflets are unavailable.
Information on dosage (dose and frequency)
Omission of this essential information from package leaflets is 
considered controversial, because although package leaflets are 
one of the most accessible and reliable sources of drug informa-
tion, some patients still prefer direct counseling from healthcare 
professionals.13 Nevertheless, it was possible to identify in this 
sample that there were some package leaflets without descriptions 
of the dose and frequency of administration, which are compul-
sory regulatory issues.9-11 Omission of dosage description might 
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be considered acceptable in some cases, for example: 1)  in  the 
case of medicines for which administration is dependent on a 
healthcare professional’s intervention (e.g. injectable forms); or 
2) in the case of complex and adjustable administration regimens, 
such as those commonly used for treating well-known chronic 
diseases, e.g. fosinopril 20 mg tablets and ramipril + hydrochloro-
thiazide 2.5 mg/12.5 mg or 5 mg/25 mg tablets for hypertension, 
because in these cases, the chronic patients (if trained) are capable 
of making the necessary adjustments to their own dosage, accord-
ing to their blood pressure. 
The qualitative analysis on the content of package leaflets 
of equivalent medicines commercialized in other countries also 
showed cases of both complete and incomplete information 
about the dosage. However, there were differences and some of 
these may be explained by the slight variances between the regu-
latory requirements of these countries (i.e. United States, United 
Kingdom and Australia). Hence, broader investigations on this 
issue are recommended.
Information on adverse reactions
Since the publication of the first Quality Review of Documents 
for Human Product Information template in 1996, both descrip-
tions of adverse reactions and dosage guidelines have been com-
pulsory items in the content of package leaflets.2,3 More recently, 
as a consequence of publication of the Quality Review of 
Documents for Human Product Information template version 8,2 
the required information on adverse reactions has become even 
more detailed. Serious adverse reactions now have to be listed 
first and these data need to be supplemented with clear instruc-
tions for patients on how to deal with them, thus confirming the 
medicines agencies’ interest in this issue.3 
According to specialized publications, in the event of omis-
sion of data on the frequency of adverse reactions, patients might 
overestimate the risk and not adhere to treatment.8,12,16 Despite 
the cultural and literacy differences between the populations of 
different countries, the impact of information on the adverse 
reactions described in package leaflets has never been specifically 
evaluated in Portugal. Following the trends of other European 
countries,2,20 almost all of the package leaflets in the sample 
included a description of adverse reactions (a compulsory regu-
latory issue) and more or less half of the package leaflets in the 
sample described the frequency of adverse reactions (an optional 
regulatory issue).2,10,11 The omission of psychomotor limitations 
in some package leaflets of anxiolytic/sedative/hypnotic drugs, 
and also hypotension, dizziness and kidney and liver toxicity in 
some leaflets of angiotensin-converting-enzyme inhibitors might 
be considered to be an issue. These situations may possibly inter-
fere with daily activities (e.g. driving) or pose other safety issues 
for patients with liver or kidney impairment.24
The lack of consistency between the contents of package leaf-
lets of equivalent medicines can be considered to be troublesome, 
given the possible interchangeability of prescriptions between 
brands of medicine with the growth in market share of generic 
drugs.22 This might be explained by: 1) the existence of optional 
regulatory topics, thus allowing marketing authorization hold-
ers to decide whether to include certain types of information 
or not (i.e. optional regulatory issues); and 2) the fact that mar-
keting authorization holders might deliberately not always pro-
vide complete information, for reasons such as the belief that the 
information is too intimidating,1 with the capability of influenc-
ing patients’ behavior, and consequently their health outcomes. 
Information on overdoses
The characteristics of overdose episodes vary from patient to 
patient, for instance with regard to: 1) the pharmacological prop-
erties of the drugs (e.g. narrow therapeutic margins may produce 
different negative events with slight differences in the doses); or 
2) the pharmaceutical forms of the medicines (e.g. parenteral 
medicines because of their usual high and fast bioavailability).24
Updated content for package leaflets with regard to overdoses is 
considered necessary, since specific descriptions of signs and what 
to do in cases of overdose were not available in many of the package 
leaflets of the sample; however, the recommendation to consult a 
physician or pharmacist was present in the majority of the pack-
age leaflets. In contrast, it was possible to identify package leaflets 
of medicines with a low likelihood of intoxication (e.g. pyritinol) 
that specifically described the symptoms and procedures in cases 
of an overdose. Regarding the descriptions of overdose symptoms 
and the specific procedures in cases of overdose described in the 
package leaflets,2 the smallest number of omissions was found in 
the package leaflets of the medicines in Group 2 (central nervous 
system), probably because of their pharmacological properties and 
the high risk associated with use of medicines from this group (e.g. 
benzodiazepines).24 With regard to appropriate actions in cases of 
overdose, this information was also sometimes omitted from the 
content of the package leaflets in other countries (e.g. it was found 
in only 75.3% of 271 German package leaflets).20
Information on the type of sentences
The updated nature and adequacy of the package leaflets in our 
sample was confirmed, given that all of them included at least 
sentence that was equal or similar (i.e. conveying an equivalent 
meaning) to those described in Table 2. This observation was 
based on the facts that all the sentences described in Table 2: 
1) are defined in the Quality Review of Documents for Human 
Product Information template 7.3.1 (the template approved 
recently); and 2) are specific to the package leaflets of medicines 
approved through a centralized procedure.2,3
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Practical implications
In addition to the usability test recommended in the guide-
lines of the European Medicines Agency,6,31 both national and 
international medicines authorities should require the use of 
algorithms or other experimental methodologies (e.g. eye-
tracking systems),32 to prove that the information included in 
the package leaflets is not only essential but also usable (e.g. 
package leaflets that are not too long).20,21,33 Contributions 
from all stakeholders are recommended with regard to devel-
oping new evidence-based guidelines (e.g. including the 
involvement of national patients), with the objective of assur-
ing optimized intelligibility of the package leaflets within the 
specific cultural context of each country. On the other hand, 
standardization of more segments of the text should be con-
sidered, such as predefinition of the different parts of the text, 
depending on the nature of the active substances of the medi-
cines. Given a higher degree of standardization, greater pro-
portions of the package leaflet text should be organized for 
each active substance that has been officially approved by the 
medicines authorities, with publication in public databases. 
This information should be made mandatory as the minimum 
necessary in each package leaflet. Publication of standardized 
parts of the text in public databases constitutes an open reg-
ulatory procedure, which would be expected to actively con-
tribute towards safe and effective use of medicines. Through 
application of the abovementioned measures, it will be possi-
ble to ensure that information in package leaflets of all thera-
peutic groups (e.g. from the central nervous, cardiovascular or 
musculoskeletal systems) is more accurate and complete, i.e. 
avoiding the differences within the obligatory or optional reg-
ulatory information that were detected in the present study. 
Overall, regulations regarding the readability of package leaf-
lets should be updated with the objectives of standardizing the 
content of package leaflets and suppressing inconsistencies 
between the package leaflets of equivalent medicines.
CONCLUSIONS
While the majority of the package leaflets of a representative 
sample of Portuguese medicines were developed in confor-
mity with compulsory regulatory issues, a small proportion 
of these leaflets needed to be updated with regard to missing 
information within their content (e.g. descriptions of doses, 
schedules and adverse reactions) and variability in the infor-
mation amongst equivalent package leaflets. The relevance 
of this updating is even greater considering that the missing 
information is often not covered during visits to physicians or 
pharmacists (e.g. descriptions of overdose symptoms or over-
dose management).  Thus, the incomplete content of some 
of the package leaflets might increase the risk of unsafe use of 
the medicines by the patients. The problems identified in this 
sample of Portuguese package leaflets probably also exist in 
the package leaflets of other European countries, since some 
of them were direct translations from the original country 
producer leaflets. 
Ideally, the methodologies for package leaflet approval 
should be optimized as a way of ensuring the inclusion of essen-
tial information for safe use of medicines, not only through 
application of guidelines but also by using experimental meth-
odologies and algorithms, which in our case would involve spe-
cifically enrolling Portuguese patients. Furthermore, future 
research and market monitoring regarding the use of package 
leaflets are advisable, e.g. creating specific forms for health pro-
fessionals or patients to communicate problems associated with 
use of package leaflets.
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